

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

PE anti-mouse F4/80 Recombinant

RRID:AB_2832547

Type: Antibody

Proper Citation

BioLegend Cat# 157304, RRID:AB_2832547

Antibody Information

URL: http://antibodyregistry.org/AB_2832547

Proper Citation: BioLegend Cat# 157304, RRID:AB_2832547

Target Antigen: F4/80

Host Organism: mouse

Clonality: recombinant monoclonal

Comments: Applications: FC

Antibody Name: PE anti-mouse F4/80 Recombinant

Description: This recombinant monoclonal targets F4/80

Target Organism: mouse

Clone ID: Clone QA17A29

Antibody ID: AB_2832547

Vendor: BioLegend

Catalog Number: 157304

Alternative Catalog Numbers: 157303

Record Creation Time: 20231110T032405+0000

Record Last Update: 20260829T034132+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-mouse F4/80 Recombinant.

No alerts have been found for PE anti-mouse F4/80 Recombinant.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Guo C, et al. (2025) BRD9 inhibition overcomes oncolytic virus therapy resistance in glioblastoma. Cell reports. Medicine, 6(8), 102258.

Zhao Y, et al. (2025) A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression. Cancer research, 85(18), 3399.

Xu H, et al. (2024) Cellular spermine targets JAK signaling to restrain cytokine-mediated autoimmunity. Immunity, 57(8), 1796.

Zheng M, et al. (2024) TNF compromises intestinal bile-acid tolerance dictating colitis progression and limited infliximab response. Cell metabolism, 36(9), 2086.

van Elsas MJ, et al. (2023) Invasive margin tissue-resident macrophages of high CD163 expression impede responses to T cell-based immunotherapy. Journal for immunotherapy of cancer, 11(3).

Righi M, et al. (2023) Enhancing CAR T-cell Therapy Using Fab-Based Constitutively Heterodimeric Cytokine Receptors. Cancer immunology research, 11(9), 1203.